Genetic and non-genetic factors affecting the response to clopidogrel therapy

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 5, 2012, Pages 663-683

  Karaźniewicz Łada, Marta ^a   Danielak, Dorota ^a   Główka, Franciszek ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Antiplatelet agents; Clopidogrel resistance; Pharmacogenetics; Response variability

Indexed keywords

ACETYLSALICYLIC ACID; ARYLDIALKYLPHOSPHATASE 1; BENZODIAZEPINE; CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; ESOMEPRAZOLE; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; GLYCOPROTEIN P; HIGH DENSITY LIPOPROTEIN; KETOCONAZOLE; LANSOPRAZOLE; LOW DENSITY LIPOPROTEIN; OMEGA 3 FATTY ACID; OMEPRAZOLE; PADGEM PROTEIN; PANTOPRAZOLE; PHENPROCOUMON; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; RIFAMPICIN; STATIN; SULFONYLUREA; UNINDEXED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; BLEEDING; BODY MASS; BRAIN ISCHEMIA; CANCER MORTALITY; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG MEGADOSE; EFFUSION; FLOW CYTOMETRY; GAIN OF FUNCTION MUTATION; GASTROINTESTINAL DISEASE; GENE EXPRESSION; GENE FREQUENCY; GENE LOCATION; GENETIC POLYMORPHISM; GENOTYPE; GLOMERULUS FILTRATION RATE; HAPLOTYPE; HAZARD RATIO; HEART INFARCTION; HEREDITY; HETEROZYGOTE; HUMAN; KIDNEY DISEASE; LOSS OF FUNCTION MUTATION; MEDLINE; META ANALYSIS; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NUCLEOTIDE SEQUENCE; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; STROKE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

EID: 84858637979     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.666524     Document Type: Review

References (143)

1. Herbert JM, Savi P. P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med 2003;3:113-22
2. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction - executive summary. J Am Coll Cardiol 2007;50:652-726
3. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary. Circulation 2004;110:588-636
4. Smith SC, Feldman TE, Hirshfeld JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention - summary article. J Am Coll Cardiol 2006;47:216-35
5. Harker LA, Boissel JP, Pilgrim AJ, Gent M. Comparative safety and tolerability of clopidogrel and aspirin: Results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Saf 1999;21:325-35
6. De Miguel A, Ibanez B, Badimon JJ. Clinical implications of clopidogrel resistance. Thromb Haemost 2008;100:196-203
7. Combescure C, Fontana P, Mallouk N, et al. Clinical implications of clopidogrel non-response in cardiovascular patients: A systematic review and meta-analysis. J Thromb Haemost 2010;8:923-33
8. Taubert D, von Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006;80:486-501 (Pubitemid 44767878)
9. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010;38:92-9
10. Bouman HJ, Schomig E, Van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011;17:110-16
11. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84:891-6
12. Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 2008;99:466-72 (Pubitemid 351549282)
13. Fontana P, Dupont A, Gandrille S, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003;108:989-95 (Pubitemid 37048230)
14. Gurbel PA, Bliden KP, Etherington A, Tantry US. Assessment of clopidogrel responsiveness: Measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. Thromb Res 2007;121:107-15 (Pubitemid 350025991)
15. Gurbel PA, Becker RC, Mann KG. Platelet function monitoring in patients with coronary artery disease. JACC 2007;50:1822-34 (Pubitemid 350007957)
16. Cattaneo M. Resistance to antiplatelet drugs: Molecular mechanisms and laboratory detection. J Thromb Haemost 2007;5:230-7 (Pubitemid 46958838)
17. Linnemann B, Schwonnberg J, Rechner AR, et al. Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y. Ann Hematol 2010;89:597-605
18. Swallow RA, Agarwala RA, Dawkins KD, Curzen NP. Thromboelastography: Potential bedside tool to assess the effects of antiplatelet therapy? Platelets 2006;17:385-92 (Pubitemid 44410502)
19. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-33
20. Bonello L, Camoin-Jau L, Armero S, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009;103:5-10
21. Results of the TRIGGER-PCI trial reported at TCT 2011. Available from: results-trigger-pci-trial-tct.html [Last accessed 26 January 2012]
22. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs. high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention. JAMA 2011;305:1097-205
23. Bonello L, Armero S, Ait Mokhtar O, et al. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism. J Am Coll Cardiol 2010;56:1630-6
24. Mega J, Hochholzer W, Frelinger AL, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011;306:2221-8
25. Yin T, Miyata T. Pharmacogenomics of clopidogrel: Evidence and perspectives. Thromb Res 2011;128:307-16
26. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the PLATO trial. Lancet 2010;376:1320-8
27. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-75
28. FDA. Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. 03-12-2010. Available from: www.fda.gov/drugs/ drugsafety/PostmarketDrugSafety InformationforPatientsandProviders/ ucm203888.htm [Last accessed 26 January 2012]
29. Rosemary J, Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: Ethnic variation and clinical significance. Curr Clin Pharmacol 2007;2:93-109 (Pubitemid 46729082)
30. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849-57
31. Fontana P, James R, Barazer I, et al. Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study. J Thromb Haemost 2011;9:1664-6
32. Barker CM, Murray SS, Teirstein PS, et al. Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity. J Am Coll Cardiol Interv 2010;3:1001-7
33. Bouman HJ, Harmsze AM, Van Werkum JW, et al. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart 2011;97:1239-44
34. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007;5:2429-36 (Pubitemid 350154353)
35. Collet JP, Hulot JS, Anzaha G, et al. High doses of clopidogrel to overcome genetic resistance: The randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). J Am Coll Cardiol Interv 2011;4:392-402
36. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet 2009;373:309-17
37. Fontana P, Hulot JS, de Moerloose P, Gaussem P. Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J Thromb Haemost 2007;5:2153-5 (Pubitemid 47450038)
38. Frere C, Cuisset T, Morange PE, et al. Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 2008;101:1088-93
39. Geisler T, Schaeffeler E, Dippon J, et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 2008;9:1251-9
40. Giusti B, Gori AM, Marcucci R, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 2009;103:806-11
41. Giusti B, Gori AM, Marcucci R, et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 2007;17:1057-64 (Pubitemid 351339490)
42. Gladding P, Webster M, Zeng I, et al. The pharmacogenetics and pharmacodynamics of clopidogrel response: A n analysis from the PRINC (Plavix Response in Coronary Intervention) trial. J Am Coll Cardiol Interv 2008;1:620-7
43. Harmsze A, Van Werkum JW, Bouman HJ, et al. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenet Genomics 2010;20:18-25
44. Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010;55:2427-34
45. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006;108:2244-7 (Pubitemid 44497506)
46. Jinnai T, Horiuchi H, Makiyama T, et al. Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan. Circ J 2009;73:1498-503
47. Kim IS, Jeong YH, Park Y, et al. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. J Am Coll Cardiol Interv 2011;4:381-91
48. Lee JM, Park S, Shin DJ, et al. Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans. Am J Cardiol 2009;104:46-51
49. Maeda A, Ando H, Asai T, et al. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine. Clin Pharmacol Ther 2011;89:229-33
50. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62
51. Oh IY, Park KW, Kang SH, et al. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart 2012;98:139-44
52. Park KJ, Chung HS, Kim SR, et al. Clinical, pharmacokinetic and pharmacogenetic determinants of clopidogrel resistance in Korean patients with acute coronary syndrome. Korean J Lab Med 2011;31:91-4
53. Park KW, Park JJ, Lee SP, et al. Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: A genetic substudy of the CILON-t randomised controlled trial. Heart 2011;97:641-7
54. Pettersen AA, Arnesen H, Opstad TB, Seljeflot I. The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel. Thromb J 2011;9:4
55. Umemura K, Furuta T, Kondo K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost 2008;6:1439-41 (Pubitemid 352016331)
56. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis. JAMA 2010;304:1821-30
57. Bauer T, Bouman HJ, Van Werkum JW, et al. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: Systematic review and meta-analysis. BMJ 2011;343:d4588
58. Holmes MV, Perel P, Shah T, et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: A systematic review and meta-analysis. JAMA 2011;306:2704-14
59. Frere C, Cuisset T, Gaborit B, et al. The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. J Thromb. Haemost. 2009;7:1409-11
60. Tiroch KA, Sibbing D, Koch W, et al. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J 2010;160:506-12
61. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19 *17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010;121:512-18
62. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006;2:1895-900 (Pubitemid 44305347)
63. Suh JW, Koo BK, Zhang SY, et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 2006;174:1715-22
64. Smith SMG, Judge HM, Peters G, et al. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. Platelets 2006;17:250-8 (Pubitemid 43890796)
65. Lee SJ, Jung IS, Jung EJ, et al. Identification of P2Y12 single-nucleotide polymorphisms and their influences on the variation in ADP-induced platelet aggregation. Thromb Res 2011;127:220-7
66. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res 2005;116:491-7 (Pubitemid 41330814)
67. von Beckerath N, von Beckerath O, Koch W, et al. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis 2005;16:199-204 (Pubitemid 40547275)
68. Motovska Z, Widimsky P, Kvasnicka J, et al. High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: A genetic substudy of PRAGUE-8 trial. Blood Coagul Fibrinolysis 2009;20:257-62
69. Staritz P, Kurz K, Stoll M, et al. Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene. Int J Cardiol 2009;133:341-5
70. Sibbing D, Koch W, Massberg S, et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 2011;32:1605-13
71. Ohmori T, Yano Y, Sakata A, et al. Lack of association between serum paraoxonase-1 activity and residual platelet aggregation during dual anti-platelet therapy. Thromb Res 2011;published online 23 November 2011; doi:10.1016/j. thromres.2011.10.033.
72. Hulot JS, Collet JP, Cayla G, et al. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv 2011;4:422-8
73. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: A pharmacogenetic analysis. Lancet 2010;376:1312-19
74. Spiewak M, Malek LA, Kostrzewa G, et al. Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes. Kardiol Pol 2009;67:827-34
75. Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol 2011;57:1251-63
76. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb. Haemost. 2009;101:714-19
77. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-60
78. Ferreiro JL, Ueno M, Capodanno D, et al. Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: Results of a prospective randomized crossover study. Circ Cardiovasc Interv 2010;3:436-41
79. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008;48:475-84 (Pubitemid 351389118)
80. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-18
81. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. J Am Med Assoc 2009;301:937-44
82. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction. Circulation 2003;107:32-7 (Pubitemid 36070929)
83. Gorchakova O, von Beckerath N, Gawaz M, et al. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 2004;25:1898-902 (Pubitemid 39452606)
84. Mitsios JV, Papathanasiou AI, Rodis FI, et al. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004;109:1335-8 (Pubitemid 38387816)
85. Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008;52:1557-63
86. Gremmel T, Steiner S, Seidinger D, et al. Calcium-channel blockers decrease clopidogrel- mediated platelet inhibition. Heart 2010;96:186-9
87. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735-41 (Pubitemid 46625113)
88. Harmsze AM, Van Werkum JW, Moral F, et al. Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients. Platelets 2011;22:98-102
89. Feher G, Koltai K, Alkonyi B, et al. Clopidogrel resistance: Body mass index and concomitant medications. Int J Cardiol 2007;120:188-92 (Pubitemid 47042251)
90. Sibbing D, von Beckerath N, Morath T, et al. Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur Heart J 2010;31:1205-11
91. Judge HM, Patil SB, Buckland RJ, et al. Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel. J Thromb. Haemost. 2010;8:1820-7
92. Gajos G, Rostoff P, Undas A, Piwowarska W. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention. The OMEGA-PCI (OMEGA-3 Fatty Acids After PCI to Modify Responsiveness to Dual Antiplatelet Therapy) Study. J Am Coll Cardiol 2010;55:1671-8
93. Lev EI, Arikan ME, Vaduganathan M, et al. Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease. J Am Coll Cardiol 2011;57:694e1-7
94. Lau WC, Welch TD, Shields T, et al. The Effect of St. John's wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: Increased platelet inhibition by enhancement of CYP 3A4 metabolic activity. J Cardiovasc Pharmacol 2011;57:86-93
95. Farhan S, Hochtl T, Kautzky-Willer A, et al. Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus. Wien Med Wochenschr 2010;160:30-8
96. Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002;90:625-8 (Pubitemid 35264538)
97. Harding SA, Sarma J, Din JN, et al. Clopidogrel reduces platelet-leucocyte aggregation, monocyte activation and RANTES secretion in type 2 diabetes mellitus. Heart 2006;92:1335-7 (Pubitemid 44298905)
98. Ang L, Palakodeti V, Khalid A, et al. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol 2008;52:1052-9
99. Angiolillo D, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005;54:2430-5 (Pubitemid 41134272)
100. Angiolillo DJ, Bernardo E, Ramirez C, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 2006;48:298-304 (Pubitemid 44026661)
101. Cuisset T, Frere C, Quilici J, et al. Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. Thromb Res 2009;123:597-603
102. El Ghannudi S, Ohlmann P, Jesel L, et al. Impaired inhibition of P2Y12 by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention. Atherosclerosis 2011;217:465-72
103. Erlinge D, Varenhorst C, Braun OO, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008;52:1968-77
104. Geisler T, Anders N, Paterok M, et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007;30:372-4 (Pubitemid 46198349)
105. Geisler T, Mueller K, Aichele S, et al. Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: Prognostic releVance of residual platelet aggregability in diabetics undergoing coronary interventions. Clin Res. Cardiol. 2010;99:743-52
106. James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: A substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2010;31:3006-16
107. Mangiacapra F, Patti G, Peace A, et al. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. Am J Cardiol 2010;106:619-23
108. Serebruany V, Pokov I, Kuliczkowski W, et al. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb. Haemost. 2008;100:76-82 (Pubitemid 351948748)
109. Van Werkum JW, Topcu Y, Postma S, et al. Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel. Thromb. Haemost. 2008;99:637-9 (Pubitemid 351549305)
110. Gaborit B, Frere C, Cuisset T, et al. Enhanced post-clopidogrel platelet reactivity in diabetic patients is independently related to plasma fibrinogen level but not to glycemic control. Thromb. Haemost. 2009;7:1939-41
111. Geisler T, Gra D, Bigalke B, et al. The residual platelet aggregation after deployment of intracoronary stent (PREDICT) score. J Thromb. Haemost. 2008;6:54-61
112. Fontana P, Berdague P, Castelli C, et al. Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study. J Thromb. Haemost. 2010;8:2614-23
113. Park SH, Kim W, Park CS, et al. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol 2009;104:1292-5
114. Angiolillo DJ, Bernardo E, Capodanno D, et al. Impact of chronic Kidney Dis.ease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 2010;55:1139-46
115. Keltai M, Tonelli M, Mann JF, et al. Renal function and outcomes in acute coronary syndrome: Impact of clopidogrel. Eur J Cardiovasc Prev Rehabil 2007;14:312-18 (Pubitemid 46650089)
116. Best PJ, Steinhubl SR, Berger PB, et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic Kidney Dis.ease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 2008;155:687-93
117. Dasgupta A, Steinhubl SR, Bhatt DL, et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA] trial). Am J Cardiol 2009;103:1359-63
118. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function results from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation 2010;122:1056-67
119. Alexopoulos D, Panagiotou A, Xanthapoulou I, et al. Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. J Thromb. Haemost. 2011;9:2379-85
120. Basili S, Pacini G, Guagnano MT, et al. Insulin resistance as a determinant of platelet activation in obese woman. J Am Coll Cardiol 2006;48:2531-8 (Pubitemid 44881227)
121. Dellas C, Schafer K, Rohm IK, et al. Leptin signaling and leptin-mediated activation of human platelets: Importance of JAK2 and the phospholipases Cgamma2 and A2. Thromb. Haemost. 2007;98:1063-71 (Pubitemid 350091136)
122. Alessi MC. Juhan-Vague I: Metabolic syndrome, haemostasis and thrombosis. Thromb. Haemost. 2008;99:995-1000
123. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: Should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 2004;16:169-74 (Pubitemid 38456448)
124. Sibbing D, von Beckerath O, Schomig A, et al. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am J Cardiol 2007;100:203-5 (Pubitemid 47041981)
125. Kelly RV, Hsu A, Topol E, Steinhubl S. The influence of body mass index on outcomes and the benefit of antiplatelet therapy following percutaneous coronary intervention. J Invasive Cardiol 2006;18:115-19
126. Soffer D, Moussa I, Harjai KJ, et al. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: Do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc Interv 2003;59:21-5 (Pubitemid 36528793)
127. Motovska Z, Widimsky P, Petr R, et al. Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: Statin's advantage and the smoking "paradox". J Cardiovasc Pharmacol 2009;53:368-72
128. Schror K. Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel. Vasc Med 1998;3:247-51 (Pubitemid 28553011)
129. Bernlochner I, Steinhubl S, Braun S, et al. Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. Thromb. Haemost. 2010;104:1193-200
130. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26
131. Park DW, Lee SW, Yun SC, et al. A point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug-eluting stent implantation. J Am Coll Cardiol 2011;58:2630-9
132. Muhlestein JB. Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Thromb. Haemost. 2010;103:71-82
133. Gori AM, Cesari F, Marcucci F, et al. The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients. Atherosclerosis 2009;202:255-62
134. Guthikonda S, Alviar CL, Vaduganathan M, et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 2008;52:743-9
135. Berger JS, Bhatt DL, Steinhubl SR, et al. Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation 2009;120:2337-44
136. Bliden KP, DiChiara J, Lawal L, et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 2008;52:531-3
137. Desai NR, Mega JL, Jiang S, et al. Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 2009;53:1273-8
138. Sibbald M, Yan AT, Huang W, et al. Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: Insights from the global registry of acute coronary events. Am Heart J 2010;160:855-61
139. Angiolillo DJ, Capranzano P, Ferreiro JL, et al. Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. Thromb. Haemost. 2011;106:253-62
140. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel. Circulation 2009;119:2553-60
141. Alexopoulos D, Dimitropoulos G, Davlouros P, et al. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: The importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv 2011;4:403-10
142. Bliden KP, Tantry US, Storey RF, et al. The effect of ticagrelor versus
143. Angiolillo DJ, Guzman LA. Clinical overview of promising nonthienopyridine antiplatelet agents. Am Heart J 2008;156:S23-8